Vaxcyte SVP Elvia Cowan sells $1.6 million in company stock

Elvia Cowan, Senior Vice President of Finance and Chief Accounting Officer at Vaxcyte, Inc. (NASDAQ:PCVX), sold 19,000 shares of the company’s common stock on October 5, 2026. The transactions, executed at a price of $86.74 per share, totaled approximately $1,648,060. The sale was carried out pursuant to a Rule 10b5-1 trading plan, which was adopted on December 8, 2025. The stock currently trades at $71.38, reflecting the market’s recent volatility despite a strong 63% gain over the past year.

Prior to the sale, Ms. Cowan acquired 19,000 shares of Vaxcyte common stock through the exercise of stock options on the same date. These options were exercised at a price of $25.92 per share, amounting to a total value of approximately $492,480. These stock options were fully vested and exercisable.

Following these transactions, Ms. Cowan directly holds 27,860 shares of Vaxcyte common stock. She also beneficially owns 74,068 stock options, which represent the right to buy an equivalent number of common shares. According to InvestingPro analysis, Vaxcyte appears overvalued at current levels relative to its Fair Value, though the company maintains a strong balance sheet with more cash than debt.

In other recent news, Vaxcyte has reported significant developments regarding its VAX-31 vaccine candidate. The OPUS-1 trial results have been a focal point, with the trial meeting its primary endpoint and achieving non-inferiority against competing vaccines. Analysts have responded positively, with BofA Securities raising its price target for Vaxcyte shares to $146, citing the successful trial data. Guggenheim also increased its price target to $125, maintaining a Buy rating. However, BofA made a slight adjustment, lowering its price target to $130 due to a revised launch timeline for the VAX-31 vaccine to 2029. BTIG reiterated its Buy rating with an $89 price target following the strong trial outcomes. Additionally, Vaxcyte announced new executive appointments, naming Luis Jodar as Chief Medical Officer and David McAvoy as Chief Legal Officer. The company also updated its timeline for the VAX-31 trial data, now expecting results by the end of October 2026.